These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates. Kubler-Kielb J; Majadly F; Biesova Z; Mocca CP; Guo C; Nussenzweig R; Nussenzweig V; Mishra S; Wu Y; Miller LH; Keith JM; Liu TY; Robbins JB; Schneerson R Proc Natl Acad Sci U S A; 2010 Jan; 107(3):1172-7. PubMed ID: 20080619 [TBL] [Abstract][Full Text] [Related]
23. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin. Martin ML; Bitzer AA; Schrader A; Bergmann-Leitner ES; Soto K; Zou X; Beck Z; Matyas GR; Dutta S Malar J; 2019 Nov; 18(1):377. PubMed ID: 31775762 [TBL] [Abstract][Full Text] [Related]
24. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487 [TBL] [Abstract][Full Text] [Related]
25. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021 [TBL] [Abstract][Full Text] [Related]
26. Structural basis for antibody recognition of the NANP repeats in Oyen D; Torres JL; Wille-Reece U; Ockenhouse CF; Emerling D; Glanville J; Volkmuth W; Flores-Garcia Y; Zavala F; Ward AB; King CR; Wilson IA Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10438-E10445. PubMed ID: 29138320 [TBL] [Abstract][Full Text] [Related]
27. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103 [TBL] [Abstract][Full Text] [Related]
28. Circumsporozoite protein as a potential target for antimalarials. Fernández-Arias C; Mashoof S; Huang J; Tsuji M Expert Rev Anti Infect Ther; 2015 Aug; 13(8):923-6. PubMed ID: 26081442 [TBL] [Abstract][Full Text] [Related]
29. Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies. Espinosa DA; Gutierrez GM; Rojas-López M; Noe AR; Shi L; Tse SW; Sinnis P; Zavala F J Infect Dis; 2015 Oct; 212(7):1111-9. PubMed ID: 25762791 [TBL] [Abstract][Full Text] [Related]
30. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum. Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382 [TBL] [Abstract][Full Text] [Related]
31. Live attenuated pre-erythrocytic malaria vaccines. Keitany GJ; Vignali M; Wang R Hum Vaccin Immunother; 2014; 10(10):2903-9. PubMed ID: 25483648 [TBL] [Abstract][Full Text] [Related]
32. Liver-Directed AAV8 Booster Vaccine Expressing Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S Front Immunol; 2021; 12():612910. PubMed ID: 34248928 [TBL] [Abstract][Full Text] [Related]
37. Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin. Carapau D; Mitchell R; Nacer A; Shaw A; Othoro C; Frevert U; Nardin E Infect Immun; 2013 Dec; 81(12):4350-62. PubMed ID: 24042110 [TBL] [Abstract][Full Text] [Related]
38. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE Malar J; 2013 Apr; 12():136. PubMed ID: 23607541 [TBL] [Abstract][Full Text] [Related]
39. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801 [TBL] [Abstract][Full Text] [Related]
40. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]